Search
A new treatment is approved for an especially aggressive kind of colorectal cancer.
Using stem cells, scientists can create batches of cortical neurons to study schizophrenia and autism.
A team of Memorial Sloan Kettering researchers reports that prostate cancer often takes an aggressive course in patients who have inherited mutations in the genes BRCA1 or BRCA2.
A targeted drug shows promise for controlling pleural mesothelioma.
An international study led by MSK researchers has found that, when used to treat large B cell lymphoma, CAR T immunotherapy may work better when given earlier in the day.
Fourth-year student Jeff Smith received a Breast Cancer Research Program Predoctoral Traineeship Award from the Department of Defense Congressionally Directed Medical Research Programs.
The pandemic has raised important issues for clinicians, and, after weighing the risks and benefits, the Colorectal Disease Management Team at MSK decided that all patients with locally advanced colorectal cancer will be treated with short-course radiation therapy rather than standard long-course chemoradiation therapy.
Breakthrough findings illustrate the promise of precision oncology and signify a paradigm shift in drug development. Interim data from three trials show a 76 percent confirmed overall response rate in patients treated with the TRK inhibitor.
A study from investigators in the Sloan Kettering Institute uncovers the details of how a key protein called GRP94 becomes disrupted, leading to cancer and other diseases.